黑素瘤ERCC1表达与替莫唑胺化疗敏感性研究

Expression of ERCC1 in tissues of maligant melanoma and clinical study onsensitivity of temozolomide-based chemotherapy

目的研究黑素瘤(malignant melanoma,MM)患者癌组织中切除修复交叉互补基因1(ERCC1)mRNA的表达及其与替莫唑胺化疗敏感性的关系。方法应用实时荧光定量PCR技术检测30例晚期MM患者中ERCC1 mRNA的表达情况,分析其与替莫唑胺化疗耐药性的关系。结果检测30例患者中ERCC1 mRNA的高表达率为56.7%(17/30),其表达在不同性别、年龄、组织学类型及临床分期中无明显差异。在ERCC1 mRNA低表达组替莫唑胺化疗有效率为46.2%,而在高表达组化疗有效率为29.4%,2组差异有统计学意义(P<0.05);ERCC1 mRNA高表达组患者的中位生存期为8.4个月,ERCC1 mRNA低表达组的中位生存期为13.6个月,其差异有统计学意义(P<0.05)。结论 ERCC1 mRNA高表达的MM患者较其低表达患者在使用替莫唑胺化疗方案时疗效差,提示ERCC1mRNA高表达的MM患者对替莫唑胺具有耐药性。同时ERCC1 mRNA低表达的患者在使用替莫唑胺化疗时有效率更高,提示我们应用ERCC1 mRNA进行检测时,患者可获得更大的益处。

Objective To investigate the expression of ERCC1 mRNA in melanoma tissues and the relationship between the genes expression and the sensitivity of temozolomide-based chemotherapy. Methods The expression of ERCC1 mRNAin 30 maligant melanoma cases were detected by RT-PCR. The relationship between the expression of ERCC1 mRNA and the sensitivity of temozolomide-based chemotherapy were explored. Results Among the relative expression levels of ERCC1 mRNA detected in 30 patients, the high expression rate of ERCC1 mRNAwas 56.7%（17/30）. The positive expression of ERCC1 mRNAhad no significant correlation with thegender, age, clinical stages and histological types（P〉0.05）. The effective rate of temozolomide chemotherapy was 46.2% in the ERCC1 mRNA low expression group, and the effective rate was significantly higher than that in the ERCC1 m RNR high expression group（29.4%）（P〈0.05）.In the ERCC1 mRNA high expression group, the median survival time was 8.4 months, while in the ERCC1 mRNAlow expression group,the median survival time was 13.6 months（P〈0.05）. Conclusion ERCC1 mRNA low expression patients have a better therapeutic effect in the use of temozolomide-based chemotherapy, which suggests that the maligant melanoma patients with high expression of ERCC1 mRNA have platinum resistance. At the same time, the patients with low expression of ERCC1 mRNA have better curative effect when treated with temozolomide-based chemotherapy, suggesting that the patients can get more benefits when ERCC1 detection is performed.